A polysaccharide composition for treating hyperlipidemia and use thereof

Abstract

The application discloses a polysaccharide composition for treating hyperlipidemia and application thereof, and belongs to the field of biological medicine. The polysaccharide composition is obtained by mixing Vansant yellow, Inonotus hispidus and Sarcodon fuligineus and then extracting with water. The polysaccharide composition can inhibit the increase of body weight and blood sugar of hyperlipidemia mice, reduce fat vacuolization and fat index, reduce the content of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and increase the content of high-density lipoprotein cholesterol, and regulate the composition and abundance of intestinal flora to improve the intestinal flora disorder phenomenon, and the effect is better than that of single polysaccharide, thereby providing a new direction for the treatment of auxiliary blood sugar reduction.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of biological medicine, in particular to a polysaccharide composition for treating hyperlipidemia and application thereof. BACKGROUND

[0002] Hyperlipidemia (HLP) is a chronic metabolic disease characterized by abnormal elevation of triglyceride (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels in the blood, and decrease of high-density lipoprotein cholesterol (HDL-C) level. This lipid metabolism disorder can significantly increase the risk of serious complications such as atherosclerosis, coronary heart disease, and cardiovascular and cerebrovascular diseases. At present, the commonly used lipid-lowering drugs in clinical practice mainly include statins, fibrates, bile acid sequestrants and niacin, etc. Although these drugs have certain efficacy, long-term use may be accompanied by adverse reactions such as liver toxicity, kidney toxicity, muscle damage, and even may induce abnormal glucose metabolism, leading to reduced patient tolerance and affecting the therapeutic effect.

[0003] In recent years, the development of natural products has become a research hotspot in the fields of medicine and functional food. Edible and medicinal fungi exhibit significant effects of lowering blood lipids, antioxidant, anti-inflammatory and immune regulation due to their rich nutritional components and diverse bioactive substances (such as polysaccharides, polyphenols, triterpenes and polypeptides, etc.). Studies have shown that active ingredients in edible and medicinal fungi can improve blood lipid levels through multiple pathways such as inhibition of cholesterol synthesis, promotion of lipid metabolism, regulation of intestinal flora, etc., and have the advantages of high safety and small toxic and side effects, providing important resources for the development of new natural lipid-lowering drugs or functional foods.

[0004] However, current research on the lipid-lowering effect of edible and medicinal fungi mainly focuses on single species or certain active ingredients, and the mechanism of action has not been fully elucidated. Moreover, the lipid-lowering efficiency, stability and bioavailability of existing products still need to be improved. Therefore, how to fully exert the synergistic effect of multi-component and multi-target of edible and medicinal fungi and develop efficient, safe and stable lipid-lowering products has become a technical problem to be solved. SUMMARY

[0005] The purpose of the present application is to provide a polysaccharide composition for treating hyperlipidemia and application thereof to solve the problems existing in the prior art. The polysaccharide composition provided by the present application can inhibit the increase of body weight and blood glucose in hyperlipidemic mice, reduce fat vacuolization and fat index, reduce the content of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and increase the content of high-density lipoprotein cholesterol, and regulate the composition and abundance of intestinal flora to improve the intestinal flora disorder, and the effect is better than that of single polysaccharide, providing a new direction for the treatment of auxiliary blood glucose reduction.

[0006] To achieve the above object, the present application provides the following scheme:

[0007] The present application provides a polysaccharide composition for treating hyperlipidemia, which is obtained by mixing Vani San Huang, Inonotus hispidus and Leucangium azerum and then extracting with water.

[0008] Optionally, the mass ratio of the Vani San Huang, the Inonotus hispidus and the Leucangium azerum is 4:3:3.

[0009] Optionally, the mass-volume ratio of the mixture of the Vani San Huang, the Inonotus hispidus and the Leucangium azerum to water is 1g:30mL.

[0010] Optionally, the extraction temperature is 90℃ and the extraction time is 3h.

[0011] Optionally, the extracted solution is further subjected to dialysis, and the molecular weight cut-off of the dialysis is 3.5kDa.

[0012] Optionally, the solution after dialysis is further subjected to precipitation with an ethanol solution, and the volume of the ethanol solution is 5.3 times the volume of the solution after dialysis.

[0013] Optionally, the solution after dialysis is further subjected to centrifugation at 5000r / min for 10min.

[0014] The present application also provides the use of the polysaccharide composition in the preparation of a medicament for treating hyperlipidemia.

[0015] The present application also provides a medicament for treating hyperlipidemia, which comprises a carrier material and / or an excipient.

[0016] The present application discloses the following technical effects:

[0017] The present application uses Vani San Huang, Inonotus hispidus and Leucangium azerum fruiting bodies as raw materials, and takes the regulation of blood lipids and the improvement of intestinal flora as evaluation standards, and verifies the effects of single edible mushroom polysaccharide and compound edible mushroom polysaccharide in improving hyperlipidemia through animal experiments, and it is found that the compound polysaccharide of the above three high-quality edible and medicinal mushroom fruiting bodies can inhibit the increase of body weight and blood sugar of hyperlipidemia mice, reduce fat vacuolation and fat index, reduce the content of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and increase the content of high-density lipoprotein cholesterol, and regulate the composition and abundance of intestinal flora to improve the intestinal flora disorder phenomenon, and the effect is better than that of single polysaccharide.

[0018] The blood lipid-lowering component provided by the present application has high-quality edible and medicinal mushrooms as raw materials, has small toxic and side effects, has simple preparation process, and will not cause unstable treatment effect due to differences between different batches of materials. The present application provides a new direction for the treatment of auxiliary blood lipid-lowering. BRIEF DESCRIPTION OF DRAWINGS

[0019] In order to more clearly illustrate the technical solutions of the embodiments of the present application or the prior art, the drawings needed in the embodiments will be briefly introduced below. Obviously, the drawings in the following description are only some embodiments of the present application, and other drawings can be obtained by those skilled in the art without creative effort on the basis of these drawings.

[0020] Figure 1 Effects of different polysaccharides on body weight of hyperlipidemia mice;

[0021] Figure 2 Effects of different polysaccharides on blood glucose levels of hyperlipidemia mice;

[0022] Figure 3 Effects of different polysaccharides on fat index of inguinal white adipose tissue (A) and epididymal white adipose tissue (B) of hyperlipidemia mice;

[0023] Figure 4 Effects of different polysaccharides on iWAT pathology of hyperlipidemia mice;

[0024] Figure 5 Effects of different polysaccharides on eWAT pathology of hyperlipidemia mice;

[0025] Figure 6 Effects of different polysaccharides on blood lipid levels of hyperlipidemia mice; wherein A is serum TC level; B is serum TG level; C is serum LDL-C level; D is serum HDL-C level;

[0026] Figure 7 Venn diagram of the number of intestinal flora species of mice in the HFD group and the HFD+CP group;

[0027] Figure 8 Difference heat map of the first 20 genera of intestinal flora of mice in the HFD group and the HFD+CP group;

[0028] In Figures 1-3 and Figure 6 , # indicates p<0.05 compared with the normal diet group, ## indicates p<0.01 compared with the normal diet group, ### indicates p<0.001 compared with the normal diet group; * indicates p<0.05 compared with the high-fat diet model group, ** indicates p<0.01 compared with the high-fat diet model group, *** indicates p<0.001 compared with the high-fat diet model group. DETAILED DESCRIPTION

[0029] The following detailed description of various exemplary embodiments of the application will not be considered limiting of the application, but rather a description of certain aspects, features, and embodiments of the application.

[0030] It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. Additionally, for a range of values of a parameter, unless otherwise stated, each intervening value of the parameter, as well as any other stated or intervening value of the parameter, is encompassed. The intervening values of the parameter are obtained by simply "slicing" or interpolating the range of values of the parameter disclosed. In instances where a parameter, such as the parameter, cannot be "sliced" or interpolated, each range of values of the parameter will be separately claimed.

[0031] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, the preferred methods and materials are described. All patents, patent applications, publications, and descriptions mentioned herein are incorporated by reference to disclose and describe the methods and / or materials in connection with which the patents, patent applications, publications, and descriptions are cited.

[0032] Many modifications and variations of this application can be made in the light of the above teachings without departing from the spirit and scope thereof. Other implementations of the application will be apparent to those skilled in the art from consideration of the specification and practice of the application disclosed herein. The examples and embodiments described herein are exemplary only and are not intended to be limiting.

[0033] As used herein, the terms "comprise", "comprising", "include", "including", "have", "having" and the like are open-ended and do not exclude additional, unrecited elements or method steps.

[0034] Examples

[0035] 1. Preparation of compound polysaccharide and single polysaccharide

[0036] (1) Preparation of compound polysaccharide:

[0037] Cleaning and physical crushing: Vani San Huang, Inonotus hispidus and Boletus luridus were cleaned and dried respectively, and then cut into pieces with a diameter of about 1 cm. The three edible fungi were crushed and passed through a 100-mesh sieve.

[0038] Compound preparation: according to weight parts, 32 parts of Vani San Huang, 24 parts of Inonotus hispidus and 24 parts of Boletus luridus (the mass ratio of the three edible fungi is 4:3:3) were taken, and the powders of the three edible fungi were mixed;

[0039] Polysaccharide extraction: take 200 g of mixed powder, add 6000 mL of deionized water, extract at 90°C for 3 h, twice, combine the extract to obtain the water extract. The extract is concentrated under reduced pressure to about 150 mL.

[0040] Dialysis: the obtained concentrated solution is placed in a 3.5 kDa dialysis bag and dialyzed in flowing water for 48 h.

[0041] Alcohol precipitation: add 95% volume concentration ethanol according to the ratio of concentrated solution: ethanol = 1:5.3 (v / v), stand overnight at 4°C, then centrifuge at 5000 r / min for 10 min, collect the precipitate, which is the compound polysaccharide.

[0042] (2) Preparation of single polysaccharide:

[0043] The preparation of single polysaccharide of V. vanthyana, I. hirsuta and B. cupressoides is the same as the above operation, only without compound preparation. After washing and physical crushing, the three edible and medicinal fungi are subjected to polysaccharide extraction and subsequent operations.

[0044] 2. Preparation of drugs

[0045] The prepared V. vanthyana polysaccharide, I. hirsuta polysaccharide, B. cupressoides polysaccharide and compound polysaccharide are prepared at a concentration of 100 mg / mL, mixed and ultrasonicated for 5 min to make them all dissolved. Common hypolipidemic drug simvastatin is used as a positive control group, prepared at a concentration of 0.6 mg / mL according to its drug component content, mixed and ultrasonicated for 10 min to make it all dissolved.

[0046] 3. Establishment of hyperlipidemia animal model and grouping of administration scheme

[0047] After adaptive feeding for one week, 42 C57BL / 6 mice of 7-8 weeks old are randomly divided into normal chow diet feeding group (NCD, n=6) and high-fat diet feeding group (HFD, n=36) according to body weight, and are fed with normal chow diet and high-fat diet respectively for 8 weeks. After successful modeling, the original feeding mode is still maintained, and the mice in the high-fat diet group are randomly divided into six groups again: high-fat diet model group (HFD), positive drug administration group (HFD+SV), V. vanthyana polysaccharide administration group (HFD+SVP), I. hirsuta polysaccharide administration group (HFD+IHP), B. cupressoides polysaccharide administration group (HFD+BAP) and compound polysaccharide administration group (HFD+CP). The feeding and administration grouping is shown in Table 1.

[0048] Table 1: Mouse grouping and administration

[0049]

[0050] The high-fat feed and ordinary feed were checked every morning at 9 o'clock during the high-fat diet modeling period (1-10 weeks) of the mice, and the insufficient and oxidized feed was supplemented or replaced in time. The mice were orally gavaged at a fixed time every day. The NCD group and the HFD group mice were gavaged with normal saline according to the body weight at 5 mL / kg; the HFD+SV group mice were gavaged with the positive drug simvastatin at 3 mg / kg; the HFD+SVP group, the HFD+IHP group, the HFD+BAP group and the HFD+CP group were gavaged with the corresponding polysaccharides at 100 mg / kg. During the 4-week gavaging process, the body weight and blood glucose changes of the mice were monitored at a fixed time: the body weight of the mice was recorded and the blood glucose was determined at the same time once a week.

[0051] 4. Animal tissue sample collection

[0052] (1) Serum: After the last gavaging of the mice, the mice were deprived of food but not water, and the tail vein blood was taken after 8 hours. The body weight of the mice was weighed and recorded before blood collection for subsequent organ index calculation. The blood of the mice was taken in a 1.5 mL EP tube, and hemolysis was avoided as much as possible during blood collection. After blood collection, the blood was placed at room temperature for 30 min, and then centrifuged using a centrifuge (3,500 rpm, 10 min). The supernatant was taken, and the above-mentioned experimental operation was repeated. The finally obtained supernatant was stored at -80℃ for later biochemical kit detection.

[0053] (2) Cecal contents: After blood collection, the mice were sacrificed using a CO2 multifunctional euthanasia system, and then immersed in alcohol for overall disinfection, and dissected in a clean bench. The mouse was cut horizontally at the approximate cecum position in the abdominal cavity, opened a small hole, found the cecum position of the mouse along the intestinal tract, cut a small hole at the top intestinal wall, and quickly took out all the cecal contents into a cryopreservation tube with forceps. After sealing with a sealing film, it was stored at -80℃ for subsequent intestinal microbiota detection.

[0054] (3) Organ tissues: After the cecal contents were taken out, the mouse was dissected to take two kinds of fat tissues iWAT and eWAT. The fat tissues need to be careful to avoid loss due to filter paper adhesion, so as to avoid affecting the accuracy of the experimental results. After the organ was treated clean, its weight was weighed on a balance and recorded for subsequent organ index calculation. After weighing, the organ tissues were quickly immersed in 4% paraformaldehyde fixing solution and stored at room temperature for fixation for subsequent histopathological observation.

[0055] 5. Inhibition of the increase of body weight of the high-fat blood mice by the compound polysaccharide

[0056] High-fat blood is closely related to obesity. High-fat blood participates in the development of obesity, and obesity can also induce lipid metabolism disorder, thereby causing high-fat blood. Therefore, the change of the body weight of the mice can partially reflect the occurrence and development state of the high-fat blood of the mice. As shown in Table 1, the body weight of the mice in the HFD group was significantly higher than that in the NCD group (P<0.01), and the body weight of the mice in the HFD+SV group was significantly lower than that in the HFD group (P<0.01).Figure 1 Results showed that after 4 weeks of drug treatment, the positive drugs simvastatin, Valsan Huang polysaccharide, Inonotus hispidus polysaccharide, Boletus luridus polysaccharide and compound polysaccharide can significantly inhibit the increase of body weight of hyperlipidemic mice, but the compound polysaccharide has the best effect of reducing body weight.

[0057] 6. Compound polysaccharide improves blood glucose level of hyperlipidemic mice

[0058] Hyperlipidemia is closely related to hyperglycemia. Abnormal elevation of blood lipid level can cause damage to glucose metabolism, i.e. lipid toxicity, which can further cause disorder of pancreatic beta cell function or insulin resistance, and cause hyperglycemia. As a metabolic disease, hyperglycemia is usually accompanied by lipid metabolism disorder, thereby causing hyperlipidemia. Therefore, the blood glucose level of mice was determined once a week during the drug administration period, and the results are shown in Figure 2 . Long-term HFD feeding leads to an increase in blood glucose level of hyperlipidemic mice. After 4 weeks of drug treatment, the positive drugs simvastatin, Valsan Huang polysaccharide, Inonotus hispidus polysaccharide, Boletus luridus polysaccharide and compound polysaccharide can significantly inhibit the blood glucose level of hyperlipidemic mice, and the compound polysaccharide has the best effect of improving blood glucose level.

[0059] 7. Compound polysaccharide inhibits the increase of fat index of hyperlipidemic mice

[0060] After the drug administration was completed, the mice were dissected, and the inguinal white adipose tissue (iWAT) and epididymal white adipose tissue (eWAT) of the mice were taken. After the surface remaining blood was absorbed with blotting paper, it was immediately weighed and the data was recorded, and finally the fat index was calculated.

[0061] Fat index (%) = fat weight (g) / mouse weight before death (g) x 100.

[0062] As shown in Figure 3 , high-fat diet can cause the increase of iWAT and eWAT index of mice, thereby causing slow lipid metabolism and fat accumulation of mice. After 4 weeks of drug treatment, the positive drugs simvastatin, Valsan Huang polysaccharide, Inonotus hispidus polysaccharide, Boletus luridus polysaccharide and compound polysaccharide can down-regulate the fat index of hyperlipidemic mice, and the compound polysaccharide has a better effect of down-regulating fat index, indicating that the compound polysaccharide can effectively alleviate lipid metabolism disorder.

[0063] 8. Compound polysaccharide alleviates fat tissue lipid droplet accumulation and fat vacuolization of hyperlipidemic mice

[0064] Long-term high-fat diet can cause a large number of fat vacuoles in the fat tissue of mice, a significant increase in the number of lipid droplets, and a high degree of fat infiltration, thereby causing lipid metabolism disorder. The results are shown in Figure 4 and Figure 5As shown, by H&E staining analysis found that after long-term high-fat diet in mice iWAT and eWAT appear a large number of fat vacuoles, lipid droplet number increased significantly. After 4 weeks of drug treatment, positive drug simvastatin, vanisang polysaccharide, rough hair pore fungus polysaccharide, copper-colored boletus polysaccharide, compound polysaccharide can significantly reduce the two kinds of fat vacuoles in hyperlipidemic mice, the number of lipid droplets and volume decrease, and the effect of compound polysaccharide group is better, indicating that compound polysaccharide can better reduce fat tissue lipid accumulation and reduce lipid infiltration.

[0065] 9. Compound polysaccharide improves blood lipid levels in hyperlipidemic mice

[0066] The TG, TC and LDL-C levels in serum can reflect the body's blood lipid metabolism to some extent, and are important indicators for monitoring blood lipid changes. Studies have shown that hyperlipidemia can cause TC, TG and LDL-C levels to rise, while HDL-C levels decrease.

[0067] TG level determination was determined according to the A110-1-1 triglyceride test kit instruction book of Nanjing Jiancheng Biological Engineering Institute. The principle is glycerol phosphate oxidase-peroxidase activator coupling method. Sample processing: dilute the serum ten times with physiological saline; add the corresponding sample or standard to the 96-well plate according to Table 2; the serum TG content (mmol / L) is determined as follows.

[0068]

[0069] Table 2 TG level measurement - 96-well plate sample addition reference table

[0070]

[0071] TC level determination was determined according to the A111-1-1 total cholesterol test kit instruction book of Nanjing Jiancheng Biological Engineering Institute. The principle is cholesterol oxidase-peroxidase coupling method. Sample processing: dilute the serum ten times with physiological saline; add the corresponding sample or standard to the 96-well plate according to Table 3; the serum TC content (mmol / L) is determined as follows.

[0072]

[0073] Table 3 TC level measurement - 96-well plate sample addition reference table

[0074]

[0075] LDL-C levels were measured according to the instructions for the Nanjing Jiancheng Bioengineering Institute A113-1-1 low-density lipoprotein cholesterol test kit. The principle is the microplate method. Sample preparation: Serum was diluted tenfold with physiological saline; the corresponding sample or standard was added to the 96-well plate according to Table 4; the serum LDL-C content (mmol / L) was measured as follows.

[0076]

[0077] Table 4 LDL-C Horizontal Measurement—Reference Table for 96-well Plate Sampling

[0078]

[0079] HDL-C levels were measured according to the instructions of the Nanjing Jiancheng Bioengineering Institute A112-1-1 High-Density Lipoprotein Cholesterol Test Kit. The principle is the microplate method. Sample preparation: Serum was diluted tenfold with physiological saline; the corresponding sample or standard was added to the 96-well plate according to Table 5; the serum HDL-C content (mmol / L) was measured as follows.

[0080]

[0081] Table 5 HDL-C Horizontal Measurement—Reference Table for 96-well Plate Sampling

[0082]

[0083]

[0084] like Figure 6 The results showed that, compared with mice fed a normal diet, the serum levels of LDL-C, TC, and TG were significantly increased, while the expression level of HDL-C was significantly decreased. After 4 weeks of treatment, the positive control drug simvastatin, *Vanilla sambac* polysaccharide, *Polyporus cirrhosa* polysaccharide, *Boletus edulis* polysaccharide, and compound polysaccharide all significantly reduced the expression levels of LDL-C, TC, and TG, while promoting the increase of HDL-C expression. The compound polysaccharide group showed better results, indicating that the compound polysaccharide can effectively improve the blood lipid levels of hyperlipidemic mice.

[0085] 9. Compound polysaccharides improve intestinal flora imbalance in hyperlipidemic mice.

[0086] The intestinal microbiota is involved in regulating the host lipid metabolism process, and the structure and functionality of the intestinal microbiota in patients with hyperlipidemia are disordered, which indicates that there is a mutual influence between the two, and there is a strong correlation between intestinal microbiota imbalance and lipid metabolism disorder. Lipid metabolism disorder can induce changes in the intestinal environment, thereby triggering internal disorders in the intestinal microbiota. A long-term high-fat diet can lead to intestinal flora disorder and a decrease in the number of flora in mice. By comparing the relative abundance distribution of differential microorganisms and genera in each group of mice, the effect of compound polysaccharides on the intestinal flora of mice can be understood.

[0087] The cecal contents of the HFD group and the HFD+CP group mice were extracted with the OMEGA Soil DNA Kit reagent box, and then the molecular size was determined and the DNA was quantified by agarose gel electrophoresis and ultraviolet spectrophotometry. According to the selection of the sequencing region, the selected V3-V4 variable region was amplified by PCR using specific primers with Barcode and high-fidelity DNA polymerase. Then, the 16S rRNA gene was amplified by PCR, and whether the effective target band could be amplified was the key to judging whether the sample quality was qualified. The conserved region of ribosomal RNA was used to design primers, and based on the limitation of Illumina NovaSeq sequencing read length and the optimal insert length range during sequencing, the V3V4 region of the bacterial 16S rRNA gene with a length of about 468bp was selected for sequencing. The specific primers in Table 6 were used for PCR amplification, wherein an oligonucleotide sequence containing 7 bases was added to the 5' end of the forward primer to distinguish different samples in the same library. The PCR amplification reaction system is shown in Table 7. After the components required for the reaction were prepared according to the table, the PCR reaction was performed. On the PCR instrument, first, pre-denaturation at 98℃ for 30s, the template DNA was fully denatured in this process, and then entered the amplification cycle. Each cycle includes three steps: template denaturation-primer annealing to template-primer extension on template. The temperature and time conditions of each cycle are as follows: 98℃ for 15s-50℃ for 30s-72℃ for 30s. The amplification cycle is repeated for 25-27 times to ensure that the number of amplified DNA fragments is sufficient, and finally, 72℃ is maintained for 5min to make the extension complete, and it is stored at 4℃.

[0088] Table 6 Primer sequences of V3-V4 variable region

[0089]

[0090] Table 7 PCR reaction program

[0091]

[0092] The product after amplification was subjected to 2% agarose gel electrophoresis, the target fragment was cut and recovered by a gel recovery kit. The preliminary quantitative results were referred to, wherein the PCR amplification recovery product was detected and quantified by a Microplate reader (dereplication) BioTek, FLx800 fluorescent quantitative system, wherein according to the sequencing amount requirement of each sample, a corresponding proportion of mixing was carried out. A library construction kit of TruSeq Nano DNALT Library Prep Kit of Illumina was used for library construction. The constructed library was subjected to quality inspection by an Agilent Bioanalyzer 2100 and a Promega QuantiFluor, wherein after the library quality inspection was qualified, sequencing was carried out. After obtaining the original sequencing data, sequencing data quality evaluation, ASV / OTU clustering and annotation were carried out. According to the clustering analysis results and research requirements, a venn diagram of the HFD group and the HFD+CP group was drawn; according to the species annotation results, the top 20 species with the highest abundance at the genus level in the HFD group and the HFD+CP group were selected, and a heat map was drawn by using the Pisono platform.

[0093] As shown in Figure 7 , there are obvious differences in the OTUs in the HFD group and the HFD+CP group, and there are 8354 and 10903 OTUs only in the HFD group and the HFD+CP group, respectively, and there are 2634 OTUs common to the HFD group and the HFD+CP group. This shows that after 4 weeks of compound polysaccharide treatment, the composition and distribution of the intestinal microbial flora are affected. Figure 8 As shown in Figure 8 , at the genus level, after 4 weeks of compound polysaccharide treatment, the relative abundance of 11 kinds of bacteria such as Dorea, Rikenella and Clostridium in hyperlipidemia mice can be significantly improved, and the relative abundance of 9 kinds of bacteria such as Flexispira, Bacteroides and Parabacteroides can be reduced, which shows that the compound polysaccharide administration can regulate the distribution and composition of the intestinal flora of hyperlipidemia mice, and further relieve the intestinal flora disorder of atherosclerotic mice.

[0094] In summary, the formula of the present application uses three edible and medicinal fungi to play the best curative effect of compound polysaccharides through careful treatment and adjustment, and can treat hyperlipidemia in a targeted manner. The compound polysaccharides can significantly inhibit the body weight and blood glucose level of hyperlipidemia mice; reduce the accumulation of lipid droplets and vacuolization in iWAT and eWAT adipose tissue, improve the fat index; reduce the content of TC, TG and LDL-C in serum, increase the expression level of HDL-C; and relieve the intestinal flora disorder of hyperlipidemia mice. And the effect is better than that of single polysaccharide.

[0095] The above described embodiments are only to illustrate the preferred modes of the present application, and are not intended to limit the scope of the present application. Any modification and improvement made by those skilled in the art to the technical solutions of the present application without departing from the design spirit of the present application shall fall within the protection scope of the present application.

Claims

1. A polysaccharide composition for treating hyperlipidemia, characterized in that, The polysaccharide composition is obtained by mixing Xanthan gum, Inonotus hispidus and Boletus aereus, and then extracting with water; The mass ratio of the Xanthan gum, the Inonotus hispidus and the Boletus aereus is 4:3:3; The mass-volume ratio of the mixture of the Xanthan gum, the Inonotus hispidus and the Boletus aereus to water is 1g:30mL; The temperature of the extraction is 90℃, and the time is 3h; The extracted solution is further subjected to dialysis, and the cut-off molecular weight of the dialysis is 3.5kDa; The solution after dialysis is further subjected to precipitation with an ethanol solution, and the volume of the ethanol solution is 5.3 times the volume of the solution after dialysis; The solution after dialysis is further subjected to precipitation with an ethanol solution, and the volume of the ethanol solution is 5.3 times the volume of the solution after dialysis; The solution after dialysis is further subjected to precipitation with an ethanol solution, and the volume of the ethanol solution is 5.3 times the volume of the solution after dialysis; 3. A medicament for treating hyperlipemia, characterized by comprising the compound of claim 1. The solution after dialysis is further subjected to precipitation with an ethanol solution, and the volume of the ethanol solution is 5.3 times the volume of the solution after dialysis; 4. The medicament according to claim 3, characterized in that, The solution after dialysis is further subjected to precipitation with an ethanol solution, and the volume of the ethanol solution is 5.3 times the volume of the solution after dialysis.

2. Use of the polysaccharide composition of claim 1 in the preparation of a medicament for treating hyperlipidemia. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide composition of claim 1. The polysaccharide

Images